Matthew Toner
InvestorVenture Partner at LongeVC
About
Matt Toner is a Venture Partner at LongeVC, where he helps portfolio companies build teams as they move from scientific proof toward commercial scale. He has more than 15 years of experience in executive search, leadership consulting, and recruitment for early-stage biotech, and was co-founder and former CEO of LifeSci Search, an executive search firm focused on early-stage biotech that grew to operate in the US, Europe, Israel, Japan, and China. His work centers on human capital strategy for biotech, including C-level hiring, board composition, and organizational design across areas such as gene and cell therapy, mRNA platforms, microbiome therapeutics, and longevity biotech.
Contact· self-published, not guessed
Invests in
BiotechLongevity
Colleagues at LongeVC
Alex Zhavoronkov
Venture Partner at LongeVC
Artem Trotsyuk
Operating Partner - US at LongeVC
Artemy Shumskiy
Principal at LongeVC
Christine Yuan Huang
Advisory Board at LongeVC
Dr. Weigao Wang
Venture Fellow at LongeVC
Evelyne Bischof
Venture Partner at LongeVC
Evgeny Izumchenko
Venture Partner at LongeVC
Garri Zmudze
Managing Partner at LongeVC
Frequently asked questions
- Who is Matthew Toner?
- Matt Toner is a Venture Partner at LongeVC, where he helps portfolio companies build teams as they move from scientific proof toward commercial scale. He has more than 15 years of experience in executive search, leadership consulting, and recruitment for early-stage biotech, and was co-founder and former CEO of LifeSci Search, an executive search firm focused on early-stage biotech that grew to operate in the US, Europe, Israel, Japan, and China. His work centers on human capital strategy for biotech, including C-level hiring, board composition, and organizational design across areas such as gene and cell therapy, mRNA platforms, microbiome therapeutics, and longevity biotech.
- Where does Matthew Toner work?
- Matthew Toner is Venture Partner at LongeVC.
- What does Matthew Toner invest in?
- Matthew Toner invests in Biotech, Longevity.